fetching data ...

SAT0161 (2020)
THE ANALGESIC EFFECT OF TOFACITINIB MAY HAVE CLINICAL SIGNIFICANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS. DATA FROM THE MOSCOW UNIFIED REGISTER OF ARTHRITIS (MUAR)
E. Zhilyaev1,2, G. Lukina3,4, E. Koltsova3,5, E. Shmidt6, K. Lytkina7
1Rheumatology Federal State Budget Institution of Additional Professional Education «Russian Medical Academy of Continuing Professional Education» Ministry of Health of Russia, Russia, Moscow, Russian Federation
2CJSC «European Medical Center», Moscow, Russian Federation
3А.S.Loginov Moscow Clinical Scientific Center, Moscow, Russian Federation
4V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
5Research Institute of the Organization of Health and Healthcare Management, Moscow, Russian Federation
6N.I.Pirogov City Clinical Hospital 1, Moscow, Russian Federation
7City Clinical Hospital 4, Moscow, Russian Federation

Background: Some theoretical data suggest that the JAK-kinase blocker tofacitinib (TOFA) may have a direct analgesic effect.


Objectives: to evaluate the clinical significance of the analgesic effect in patients with rheumatoid arthritis (RA) in real clinical practice.


Methods: Hypothesis being tested: the analgesic effect of TOFA may be manifested by a decrease in the ratio of subjective to objective indicators of arthritis activity.

Data from RA patients receiving biologics (bDMARD) and/or TOFA and included in the MUAR register were analyzed. The tender joints count (TJC), the HAQ-DI functional ability index, and the RAPID3 disease activity index were considered as subjective estimates. The swollen joints count (SJC) and the level of CRP were treated as objective indicators. The estimation of quotients from the division of subjective indicators into objective ones in all combinations is made.

Taking into account the observational nature of the study, we searched for confounders for each of these ratios. Comparison of the calculated indices during the treatment with various targeted DMARDs (tDMARDs) was made with an adjustment for the detected confounders.


Results: the analysis included 944 treatment episodes in 832 patients, including 93 episodes of TOFA treatment. The average age was 55.3 ± 12.4 years, women - 698 (83.9%), seropositive for RF -672 (80.8%). The analysis of the adjusted values showed that the ratios of the TJC, HAQ-DI and RAPID3 to the SJC during the treatment with TOFA was significantly lower than with tDMARDs on average. There were no significant differences in the ratios of objective indicators to the CRP level (Table).

Ratios of objective and subjective indicators during the treatment with tofacitinib and with tDMARDs therapy in general


Conclusion: the severity of subjective feelings and functional disorders in RA patients receiving TOFA may be less with the same level of objective signs of arthritis compared with bDMARDs.


Disclosure of Interests: Evgeniy Zhilyaev Speakers bureau: Novartis, UCB, Pfizer, Biocad, Abbvie, MSD, Roche, Galina Lukina Speakers bureau: Novartis, Pfizer, UCB, Abbvie, Biocad, MSD, Roche, Ekaterina Koltsova: None declared, Evgeniya Shmidt Speakers bureau: MSD, Novartis, Pfizer, Karine Lytkina Speakers bureau: Novartis, Eli Lilly, Pfizer, UCB, Abbvie, Biocad, MSD, Jonson&Jonson

Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1017
Session: Rheumatoid arthritis - non biologic treatment and small molecules (Poster Presentations)